BEAT Stock Summary and Trading Ideas (Heartbeam | NASDAQ:BEAT)

HeartBeam Inc is a medical technology company is focusing on developing and commercializing higher resolution ambulatory Electrocardiogram ("ECG") solutions that enable the detection and monitoring of cardiac disease outside a healthcare facility setting. The Company's ability to develop higher-resolution ECG solutions is achieved through the development of the Company's proprietary and patented Vector Electrocardiography ("VECG") technology platform. The Company has validated this technology and is seeking U.S. Food and Drug Administration ("FDA") clearance for its initial telehealth products.

Heartbeam trades on the NASDAQ stock market under the symbol BEAT.

As of March 18, 2026, BEAT stock price declined to $1.25 with 118,615 million shares trading.

BEAT has a beta of 1.19, meaning it tends to be more sensitive to market movements. BEAT has a correlation of 0.02 to the broad based SPY ETF.

BEAT has a market cap of $43.05 million. This is considered a Sub-Micro Cap stock.

Last quarter Heartbeam reported $0 in Revenue and -$.14 earnings per share. This fell short of revenue expectation by $-200,000 and missed earnings estimates by -$.01.

In the last 3 years, BEAT traded as high as $4.00 and as low as $.54.

The top ETF exchange traded funds that BEAT belongs to (by Net Assets): VTI, VXF, IWC.

BEAT has underperformed the market in the last year with a price return of -40.8% while the SPY ETF gained +19.0%. BEAT has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -59.3% and -15.0%, respectively, while the SPY returned -0.2% and -1.8%, respectively.

BEAT support price is $1.21 and resistance is $1.40 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BEAT shares will trade within this expected range on the day.